Identifying sources of interindividual pharmacokinetic variability with population modeling: Commentary on Joerger et al., p. 2150

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 1951-1953

  Sparreboom, Alex ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOTOXIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG;

BODY SURFACE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; EDITORIAL; GENETIC VARIABILITY; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHARMACODYNAMICS; PHARMACOGENETICS; POPULATION MODEL; PRIORITY JOURNAL; SEX DIFFERENCE;

ANTI-INFECTIVE AGENTS; DRUG MONITORING; HUMANS; INDIVIDUALITY; MODELS, BIOLOGICAL; POPULATION; SEX FACTORS;

EID: 33646244052     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0342     Document Type: Editorial

References (22)

1. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21.
2. Rombout F, Aarons L, Karlsson M, et al. Modelling and simulation in the development and use of anticancer agents: an underused tool? J Pharmacokinet Pharmacodyn 2004;31:419-40.
3. Joerger M, Huitema AD, Van den Bongard HJ, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function and body size on the population pharmacokinetics of paclitaxel in solid tumor patients. Clin Cancer Res 2006;12:2150-7.
4. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005;6:780-9.
5. Sparreboom A, Verweij J. Paclitaxel pharmacokinetics, threshold models and dosing strategies. J Clin Oncol 2003;21:2803-4.
6. Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Retain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 2004;10:8325-31
7. Mross K, Hollander N, Unger C, Massing U. Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications. Int J Clin Pharmacol Ther 2005;43:601-2.
8. De Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004;54:105-12
9. Loos WJ, De Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body-surface area values. J Clin Oncol. In press 2006.
10. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-5.
11. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199:193-209.
12. Schuetz EG, Furuya KN, Scheutz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275:1011-8.
13. Singh S, Parulekar W, Murray N, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 2005;23:850-6.
14. Davis M. Gender differences in P-glycoprotein: drug toxicity and response. J Clin Oncol 2005;23: 6439-40.
15. Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005;45:674-82.
16. Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005;11:8097-104.
17. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4:815-8.
18. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005;57:573-8.
19. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116:824-9.
20. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 2004;64:4927-30.
21. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3:833-8.
22. Childs S, Yeh RL, Hui D, Ling V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res 1998;58:4160-7.